Chronic Lymphocytic Leukemia: VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
Acute Myeloid Leukemia: VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.